Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
The company hopes to develop cancer treatments based on individualized gene therapies, and has two promising pipeline candidates.
A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."
ATNX earnings call for the period ending September 30, 2021.
ATNX earnings call for the period ending June 30, 2021.
ATNX earnings call for the period ending March 31, 2021.
ATNX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.